- Home
- IMOS vs TARS Comparison
IMOS vs TARS Comparison
Compare IMOS & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMOS | TARS |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMOS | TARS |
|---|---|---|
| Price | $60.54 | $62.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | 104.7K | ★ 529.2K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $21.75 | $56.43 |
| Revenue Next Year | $4.21 | $30.19 |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $15.06 | $38.51 |
| 52 Week High | $72.91 | $85.25 |
Technical Indicators
Market Signals| Indicator | IMOS | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 46.90 |
| Support Level | $55.12 | $60.95 |
| Resistance Level | $61.27 | $66.36 |
| Average True Range (ATR) | 3.00 | 2.87 |
| MACD | -0.57 | 0.39 |
| Stochastic Oscillator | 29.71 | 27.43 |
Price Performance
Historical ComparisonAbout IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.